Maternal Use of Drugs for Cardiovascular Diseases and Infant Congenital Malformations

  • Bengt Källén


There is a clear-cut increased risk for some malformations and notably for cardiovascular defects when the mother has used anti-hypertensives during early pregnancy. There seems to be no certain difference between drugs with different mechanisms of action in this association and an increased risk is also seen in infants of women with a diagnosis of hypertension but without any reported use of anti-hypertensive drugs. It seems likely that the effect is due to confounding by indication, that is, an effect of underlying hypertension. The Swedish data add little to the knowledge of risks with other drugs used for cardiovascular disease, e.g., statins. The largest study in the literature suggests no direct teratogenic effect of statins but more information is needed.


  1. Bánhidy F, Acs N, Puhó EH, Czeizel AE. Chronic hypertension with related drug treatment of pregnant women and congenital abnormalities in their offspring: a population-based study. Hypertens Res. 2011;34:257–63.CrossRefGoogle Scholar
  2. Bánhidy F, Szilasi M, Czeizel AE. Association of pre-eclampsia with or without superimposed chronic hypertension in pregnant women with the risk of congenital abnormalities in their offspring: a population-based case-control study. Eur J Obstet Gynecol Reprod Biol. 2012;163:17–21.CrossRefGoogle Scholar
  3. Bateman BT, Hernandez-Dias S, Fischer MA, Seely EW, Ecker JL, Franklin JM, Desai R, Allen-Coleman C, Mogun H, Avom A, Huybrechts KF. Statins and congenital malformations: cohort study. BMJ. 2015;350:h1035. Scholar
  4. Bergman JEH, Lutke R, Gans ROB, Addor M-C, Barisic I, Cavero-Carbonell C, Garne E, Gatt M, Klungsoyr K, Lelong N, Lynch C, Mokoroa O, Nelen V, Neville AJ, Pierini A, Randrianaivo H, Rissman A, Tucker D, Wiesel A, Dolk H. Beta-blocker use in pregnancy and risk of specific congenital anomalies: a European case-malformed control study. Drug Saf. 2018;41:415–27.CrossRefGoogle Scholar
  5. Brent RL, Beckman DA. Angiotensin-converting enzyme inhibitors, an embryopathic class of drugs with unique properties. Information for clinical teratology counselors. Teratology. 1991;43:543–6.CrossRefGoogle Scholar
  6. Caton AR, Bell EM, Druschel CM, Werler MM, Lin AE, Browne ML, McNutt L-A, Romitti PA, Mitchell AA, Olney RS, Correa A. Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations. Hypertension. 2009;54:63–70.CrossRefGoogle Scholar
  7. Cooper WO, Hernandez-Dias S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, Hall K, Ray WA. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354:2443–51.CrossRefGoogle Scholar
  8. Diav-Citrin O, Schechtman S, Halberstadt Y, Finkel-Pekarsky V, Wajnberg R, Arnon J, Di Gianantonio E, Clementi NM, Ornoy A. Pregnancy outcome after exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Reprod Toxicol. 2011;31:540–5.CrossRefGoogle Scholar
  9. Edison RJ, Muenke M. Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am J Med Genet. 2004;131A:287–98.CrossRefGoogle Scholar
  10. Gibb H, Scialli AR. Statin drugs and congenital anomalies. Am J Med Genet. 2005;135A:230–1.CrossRefGoogle Scholar
  11. Heinonen OP, Slone D, Shapiro S. Birth defects and drugs in pregnancy. Littleton, MA: Publishing Sciences Group; 1977.Google Scholar
  12. Lennestål R, Otterblad Olausson P, Källén B. Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. Eur J Clin Pharmacol. 2009;65:615–25.CrossRefGoogle Scholar
  13. Li D-K, Yang C, Andrade S, Tavares V, Ferber JR. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. BMJ. 2011;343:d5931. Scholar
  14. Liu S, Lisonkova S, Rouleau J, Van den Hof M, Sauve R, Kramer MS. Association between maternal chronic conditions and congenital heart defects: a population-based cohort study. Circulation. 2013;128:583–9.CrossRefGoogle Scholar
  15. Manson JM, Freyssinges C, Ducrocq MB, Stephenson WP. Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy. Reprod Toxicol. 1996;10:439–46.CrossRefGoogle Scholar
  16. Nakhai-Pour HR, Rey E, Bérard A. Antihypertensive medication use during pregnancy and the risk of major congenital malformations or small-for-gestational-age newborns. Birth Defects Res A Clin Mol Teratol. 2010;89:147–54.Google Scholar
  17. Ofori B, Rey E, Bérard A. Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol. 2007;64:496–509.CrossRefGoogle Scholar
  18. Petersen EE, Mitchell AA, Carey JC, Werler MM, Louik C, Rasmussen SA. Maternal exposure to statins and risk for birth defects: a case-series approach. Am J Med Genet A. 2008;146A:2701–5.CrossRefGoogle Scholar
  19. Piper JM, Ray WA, Rosa FW. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors. Obstet Gynecol. 1992;80:429–32.PubMedGoogle Scholar
  20. Pollack PS, Shields KE, Burnett DM, Osborne MJ, Cunningham ML, Stepanavage ME. Pregnancy outcome after maternal exposure to simvastatin and lovastatin. Birth Defects Res A Clin Mol Teratol. 2005;73:888–96.CrossRefGoogle Scholar
  21. Sandström B. Antihypertensive treatment with the adrenergic blocker metoprolol during pregnancy. Gynecol Invest. 1978;9:195–204.CrossRefGoogle Scholar
  22. Steffensen FH, Nielsen GI, Sørensen HT, Olsen C, Olsen J. Pregnancy outcome with ACE-inhibitor use in early pregnancy. Lancet. 1998;351:596.CrossRefGoogle Scholar
  23. Tagushi N, Rubin ET, Hosokawa A, Choi J, Ying AY, Moretti ME, Koren G, Ito S. Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes. Reprod Toxicol. 2008;26:175–7.CrossRefGoogle Scholar
  24. Toleikyte I, Retterstøl K, Leren TP, Iversen PO. Pregnancy outcome in familial hypercholesterolemia. Circulation. 2011;124:1606–14.CrossRefGoogle Scholar
  25. Van Zutphen AR, Werler MM, Browne MM, Romitti PA, Bell EN, LA MN, Druschel C, Mitchell AA, for the National Birth Defects Prevention Study. Maternal hypertension, medication use, and hypospadias in the National Birth Defects Prevention Study. Obstet Gynecol. 2014;123:309–17.CrossRefGoogle Scholar
  26. Vasilakis-Scaramozza C, Aschengrau A, Cabral HJ, Jisk SS. Antihypertensive drugs and the risk of congenital anomalies. Pharmacotherapy. 2013;33:476–82.CrossRefGoogle Scholar
  27. Weber-Schoendorfer C, Hannemann D, Meister R, Eléfant E, Cuppers-Maarschalkerweerd B, Arnon J, Vial T, Rodriguez-Pinilla E, Clementi M, Robert-Gnansia E, de Santis M, Malm H, Dolico A, Schaefer C. The safety of calcium channel blockers during pregnancy: a prospective, multicenter, observational study. Reprod Toxicol. 2008;26:24–30.CrossRefGoogle Scholar
  28. Winterfeld U, Allignol A, Panchaud A, Rothuizen LE, Perlob P, Cuppers-Maarschalkerweerd B, Vial T, Stephens S, Clementi M, De Santis M, Pistelli A, Berlin M, Eleftheriou G, Manákovcá E. Pregnancy outcome following maternal exposure to statins: a multicenter prospective study. BMJ. 2013;120:463–71.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Bengt Källén
    • 1
  1. 1.Tornblad Institute for Comparative EmbryologyLund UniversityLundSweden

Personalised recommendations